AlphaYou
Overview
Smart money at a glance
Filings to Oct 5, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 5- Open
- $1.19
- 52-wk high
- $2.62
- High
- $1.19
- 52-wk low
- $1.09
- Low
- $1.15
- Prev close
- $1.16
- Mkt cap
- $179.2M
- Volume
- 1.18M
- Fwd P/E
- 41.1x
- Beta
- 0.94
- P/S
- 3.5x
- P/B
- 3.2x
- Profit margin
- -259.4%
- Op margin
- -226.0%
- ROE
- -178.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CHRS filings
Are insiders buying or selling Coherus BioSciences Inc (CHRS) stock?
Neither. Coherus BioSciences Inc (CHRS) insiders filed no open-market purchases or sales in the 90 days to Oct 5, 2026, according to SEC Form 4 filings.
Which members of Congress have traded CHRS recently?
None. No member of Congress disclosed a CHRS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CHRS smart-money data?
This summary uses filings available on Oct 5, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
How top traders are positioned
No tracked top-trader positions in CHRS right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 37.5% below what analysts expected.
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.16 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | -$0.22 / -$0.16Alpha Vantage | -37.50% miss | Unavailable | Unavailable |
| Mar 31, 2026 | May 11, 2026 | -$0.25 / -$0.26Alpha Vantage | +3.85% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 9, 2026 | -$0.34 / -$0.34Alpha Vantage | -0.53% in line | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$0.33 / -$0.29Alpha Vantage | -13.79% miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$0.39 / -$0.25Alpha Vantage | -56.00% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 12, 2025 | -$0.35 / -$0.22Alpha Vantage | -59.09% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 10, 2025 | -$0.28 / -$0.13Alpha Vantage | -114.56% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | -$0.01 / -$0.11Alpha Vantage | +90.91% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 5, 2026, in 31 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -259.4%
- Forward P/E
- 41.15
- Market cap
- $179M
Valuation
- P/S3.52
- P/B3.19
Quality
- Operating margin-226.0%
- ROE-178.4%
- ROA-30.5%
Growth
- Beta0.94
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace